Publisher Correction: Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer

被引：0

作者：

Mathilde Louise Gehrchen ^{[1
]}

Tobias Berg ^{[1
]}

Rasmus Garly ^{[2
]}

Maj-Britt Jensen ^{[1
]}

Saskia Eßer-Naumann ^{[1
]}

Jeanette Dupont Rønlev ^{[3
]}

Hanne Melgaard Nielsen ^{[4
]}

Ann Knoop ^{[5
]}

Iben Kümler ^{[1
]}

机构：

[1] Copenhagen University Hospital,Danish Breast Cancer Group, Department of Oncology

[2] Rigshospitalet,Department of Oncology

[3] Copenhagen University Hospital,Department of Oncology

[4] Rigshospitalet,Department of Oncology

[5] Næstved Hospital,Department of Oncology

[6] University Hospital of Odense,Department of Oncology

[7] Aarhus University Hospital,Department of Clinical Medicine, Faculty of Health and Medical Sciences

[8] Herlev and Gentofte University Hospital,undefined

[9] University of Copenhagen,undefined

来源：

BJC Reports | / 2卷 / 1期

关键词：

D O I：

10.1038/s44276-024-00083-5

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice
West, Malinda T.
Smith, Claire E.
Kaempf, Andy
Kohs, Tia C. L.
Amirsoltani, Ramin
Ribkoff, Jessica
Choung, Josh Lee
Palumbo, Alison
Mitri, Zahi
Shatzel, Joseph J.
EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (05) : 634 - 642
[22] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
Perrone, Valentina
Dovizio, Melania
Leogrande, Melania
Tamma, Antonella
Giovannitti, Massimo
Buzzoni, Carlotta
Esposti, Luca Degli
BREAST CANCER MANAGEMENT, 2023, 12 (02)
[23] Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
West, Malinda T.
Goodyear, Shaun M.
Hobbs, Evthokia A.
Kaempf, Andy
Kartika, Thomas
Ribkoff, Jessica
Chun, Brie
Mitri, Zahi, I
ONCOLOGIST, 2023, : 682 - 690
[24] Real-world evidence evaluating continuation of CDK4/6 inhibitors beyond first progression in hormone receptor-positive (HR plus ) metastatic breast cancer.
Eziokwu, Akaolisa Samuel
Varella, Leticia
Kruse, Megan Lynn
Jia, Xuefei
Moore, Halle C. F.
Budd, George Thomas
Abraham, Jame
Montero, Alberto J.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[25] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
Ettl, Johannes
Huober, Jens
Lueftner, Diana
Marme, Frederik
Wuerstlein, Rachel
BREAST CARE, 2017, 12 (02) : 118 - 120
[26] Real-world benefit of CDK4/6 inhibitor and endocrine therapy combination in metastatic breast cancer and correlation with neutropenia
Jenneman, Dakota
Zhong, Xiaojun
Ma, Junjie
Sun, Weihong
Han, Heather
Soliman, Hatem
Loftus, Loretta
Costa, Ricardo
Armaghani, Avan
Soyano, Aixa
Czerniecki, Brian
Lee, M. Catherine
Kiluk, John
Khakpour, Nazanin
Hoover, Susan
Laronga, Christine
Khong, Hung T.
CANCER RESEARCH, 2020, 80 (04)
[27] Real-World Quality-of-Life Data in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors Using Four Assessment Tools
Stanciu, Ioana-Miruna
Nitipir, Cornelia
CANCERS, 2025, 17 (05)
[28] Determinants of response to CDK4/6 inhibitors in the real-world setting
Witkiewicz, Agnieszka K.
Schultz, Emily
Wang, Jianxin
Hamilton, Deanna
Levine, Ellis
O'Connor, Tracey
Knudsen, Erik S.
NPJ PRECISION ONCOLOGY, 2023, 7 (01)
[29] Determinants of response to CDK4/6 inhibitors in the real-world setting
Agnieszka K. Witkiewicz
Emily Schultz
Jianxin Wang
Deanna Hamilton
Ellis Levine
Tracey O’Connor
Erik S. Knudsen
npj Precision Oncology, 7
[30] Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Kimmick, G.
Pilehvari, A.
You, W.
Bonilla, G.
Anderson, R.
ANNALS OF ONCOLOGY, 2023, 34 : S373 - S373

← 1 2 3 4 5 →